Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: Minimal activity in colorectal cancer

Sridhar Mani; John W. Kugler; James A. Knost; David F. Sciortino; Joseph Gibbons; Juan C. Garcia; Rafat H. Ansari; Richard L. Schilsky; Everett E. Vokes

doi:10.1023/A:1006100116229

Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: Minimal activity in colorectal cancer

Sridhar Mani, John W. Kugler, James A. Knost, David F. Sciortino, Joseph Gibbons, Juan C. Garcia, Rafat H. Ansari, Richard L. Schilsky, Everett E. Vokes

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

Metastatic colorectal cancer is very common in the Western hemisphere and current treatment modalities are not effective. In this study a prolonged (150-minute) infusion of gemcitabine at a constant dose rate of 10 mg/m²/min administered weekly for 3 consecutive weeks repeated every 4 weeks revealed a response rate of 4% (90% CI < 1%-18%). There were no complete responses. Treatment with gemcitabine produced moderate to severe toxicity as grade 3-4 neutropenia requiring dose modification was seen in 40% of patients treated. When used in this dose and schedule, gemcitabine does not appear to be effective for patients with metastatic colorectal cancer.

Original language	English (US)
Pages (from-to)	275-278
Number of pages	4
Journal	Investigational New Drugs
Volume	16
Issue number	3
DOIs	https://doi.org/10.1023/A:1006100116229
State	Published - 1998
Externally published	Yes

Keywords

150 Minutes
Colorectal cancer
Gemcitabine
Phase II

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1023/A:1006100116229

Cite this

@article{23659676ff954116876b2939d068794d,

title = "Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: Minimal activity in colorectal cancer",

abstract = "Metastatic colorectal cancer is very common in the Western hemisphere and current treatment modalities are not effective. In this study a prolonged (150-minute) infusion of gemcitabine at a constant dose rate of 10 mg/m2/min administered weekly for 3 consecutive weeks repeated every 4 weeks revealed a response rate of 4% (90% CI < 1%-18%). There were no complete responses. Treatment with gemcitabine produced moderate to severe toxicity as grade 3-4 neutropenia requiring dose modification was seen in 40% of patients treated. When used in this dose and schedule, gemcitabine does not appear to be effective for patients with metastatic colorectal cancer.",

keywords = "150 Minutes, Colorectal cancer, Gemcitabine, Phase II",

author = "Sridhar Mani and Kugler, {John W.} and Knost, {James A.} and Sciortino, {David F.} and Joseph Gibbons and Garcia, {Juan C.} and Ansari, {Rafat H.} and Schilsky, {Richard L.} and Vokes, {Everett E.}",

note = "Funding Information: Supported by an investigator-initiated grant through Eli Lilly Co., Inc., Indianapolis, IN and the UCCRC Support Grant #CA 14599 and the National Cancer Institute Contract NO1-CM-07301.",

year = "1998",

doi = "10.1023/A:1006100116229",

language = "English (US)",

volume = "16",

pages = "275--278",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer

T2 - Minimal activity in colorectal cancer

AU - Mani, Sridhar

AU - Kugler, John W.

AU - Knost, James A.

AU - Sciortino, David F.

AU - Gibbons, Joseph

AU - Garcia, Juan C.

AU - Ansari, Rafat H.

AU - Schilsky, Richard L.

AU - Vokes, Everett E.

N1 - Funding Information: Supported by an investigator-initiated grant through Eli Lilly Co., Inc., Indianapolis, IN and the UCCRC Support Grant #CA 14599 and the National Cancer Institute Contract NO1-CM-07301.

PY - 1998

Y1 - 1998

N2 - Metastatic colorectal cancer is very common in the Western hemisphere and current treatment modalities are not effective. In this study a prolonged (150-minute) infusion of gemcitabine at a constant dose rate of 10 mg/m2/min administered weekly for 3 consecutive weeks repeated every 4 weeks revealed a response rate of 4% (90% CI < 1%-18%). There were no complete responses. Treatment with gemcitabine produced moderate to severe toxicity as grade 3-4 neutropenia requiring dose modification was seen in 40% of patients treated. When used in this dose and schedule, gemcitabine does not appear to be effective for patients with metastatic colorectal cancer.

AB - Metastatic colorectal cancer is very common in the Western hemisphere and current treatment modalities are not effective. In this study a prolonged (150-minute) infusion of gemcitabine at a constant dose rate of 10 mg/m2/min administered weekly for 3 consecutive weeks repeated every 4 weeks revealed a response rate of 4% (90% CI < 1%-18%). There were no complete responses. Treatment with gemcitabine produced moderate to severe toxicity as grade 3-4 neutropenia requiring dose modification was seen in 40% of patients treated. When used in this dose and schedule, gemcitabine does not appear to be effective for patients with metastatic colorectal cancer.

KW - 150 Minutes

KW - Colorectal cancer

KW - Gemcitabine

KW - Phase II

UR - http://www.scopus.com/inward/record.url?scp=0032428290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032428290&partnerID=8YFLogxK

U2 - 10.1023/A:1006100116229

DO - 10.1023/A:1006100116229

M3 - Article

C2 - 10360609

AN - SCOPUS:0032428290

SN - 0167-6997

VL - 16

SP - 275

EP - 278

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 3

ER -

Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: Minimal activity in colorectal cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this